Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection

99mTc-trofolastat (99mTc-MIP-1404), a small-molecule inhibitor of prostate-specific membrane antigen, shows high potential to detect prostate cancer (PCa) noninvasively using SPECT. We therefore wanted to assess the performance of 99mTc-trofolastat SPECT/CT in a phase 2 multicenter, multireader prospective study in patients with intermediate- and high-grade PCa, before radical prostatectomy and extended pelvic lymph node (LN) dissection, with histopathology as the gold standard. Methods: PCa patients (n = 105) with an increased risk of LN involvement (LNI) underwent pelvic 99mTc-trofolastat SPECT/CT before radical prostatectomy with extended pelvic LN dissection. The sensitivity of 99mTc-trofolastat for detection of PCa on a patient and lobe basis, using visual and semiquantitative (tumor-to-background ratio [TBR]) scores, and of LNI was evaluated as well as the correlation of uptake within the gland to Gleason scores (GS) and assessment of the predictive potential of 99mTc-trofolastat uptake for LNI. Results: PCa was detected in 98 patients (94%) with acceptable variability between readers. There was a significantly higher visual score and TBR in positive lobes compared with tumor-negative lobes. Receiver-operating characteristic analysis showed that visual scores more accurately discriminated lobes with GS ≤ 3 + 3 from ≥ 3 + 4, whereas TBRs discriminated high-grade disease from normal lobes better. Visual scores and TBRs correlated significantly with GS. 99mTc-trofolastat SPECT/CT detected LNI with a sensitivity of 50% and specificity of 87%, and TBR values significantly predicted LNI with a sensitivity of 90%. Conclusion: 99mTc-trofolastat SPECT/CT detects PCa with high sensitivity in patients with intermediate- and high-risk PCa compared with histology. It has the potential to be used as a surrogate marker for GS and predict LNI.

[1]  Toby C. Cornish,et al.  18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[2]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[3]  K. Rahbar,et al.  Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study , 2015, EJNMMI Research.

[4]  M. Haider,et al.  The expanding role of MRI in prostate cancer. , 2013, AJR. American journal of roentgenology.

[5]  S. Vallabhajosula,et al.  Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Vallabhajosula,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer , 2014, The Journal of Nuclear Medicine.

[7]  William C. Eckelman,et al.  First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[8]  Esther Mena,et al.  Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer , 2015, Molecular Imaging and Biology.

[9]  H. Heinzer,et al.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.

[10]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  D. Bostwick,et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.

[12]  M. Bock,et al.  MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  P. Wolf,et al.  Targeted therapies for prostate cancer against the prostate specific membrane antigen. , 2009, Current drug targets.

[14]  G. Reischl,et al.  PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen , 2009, Journal of Nuclear Medicine.

[15]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[16]  W. Eckelman,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[17]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Guilherme Godoy,et al.  Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. , 2011, European urology.

[19]  Hedvig Hricak,et al.  Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[20]  K. Rahbar,et al.  Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[21]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[22]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[23]  Clemens Decristoforo,et al.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  T. Holland-Letz,et al.  Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  M. Schwaiger,et al.  Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[26]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[27]  S. Landas,et al.  Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues , 2006, World Journal of Surgery.

[28]  U. Haberkorn,et al.  [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Namkug Kim,et al.  Functional MR imaging of prostate cancer. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[30]  N. Bander,et al.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.

[31]  M. Picchio,et al.  Initial prostate cancer diagnosis and disease staging—the role of choline-PET–CT , 2015, Nature Reviews Urology.